Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis:Results from the BioDay Registry

Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentre prospective study evaluated the effectiveness and safety of 16-weeks' treatment with baricitinib in adult patients with moderate-to-severe atopic dermatitis in daily practice. A total of 51 patients from the BioDay registry treated with baricitinib were included and evaluated at baseline and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed using clinician- and patient-reported outcome measurements. Adverse events and laboratory assessments were evaluated at every visit. At week 16, the probability (95% confidence interval) of achieving Eczema Area and Severity Index ≤ 7 and numerical rating scale pruritus ≤ 4 was 29.4% (13.1-53.5) and 20.5% (8.8-40.9), respectively. No significant difference in effectiveness was found between dupilumab non-responders and responders. Twenty-two (43.2%) patients discontinued baricitinib treatment due to ineffectiveness, adverse events or both (31.4%, 9.8% and 2.0%, respectively). Most frequently reported adverse events were nausea (n = 6, 11.8%), urinary tract infection (n = 5, 9.8%) and herpes simplex infection (n = 4, 7.8%). In conclusion, baricitinib can be an effective treatment option for moderate-to-severe atopic dermatitis, including patients with non-responsiveness on dupilumab. However, effectiveness of baricitinib is heterogeneous, which is reflected by the high discontinuation rate in this difficult-to-treat cohort

Identification of Risk Factors for Dupilumab-associated OculaSurface Disease in Patients with Atopic Dermatitis

This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associated ocular surface di-sease, by performing univariate and multivariate logistic regression analyses. A total of 469 patients were included, of which 152/469 (32.4%) developed dupi-lumab-associated ocular surface disease. Multivariate analysis showed a statistically significant association of the development of dupilumab-associated ocular surface disease with a history of any eye disease (his-tory of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at the start of dupilumab (odds ratio 5.16, 95% confidence interval 2.30–11.56, p < 0.001). In conclusion, a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis ex-cluded) combined with the use of ophthalmic medication at baseline was associated with the development of dupilumab-associated ocular surface disease in patients with atopic dermatitis

Prognostic significance of DNA methylation profiles at MRI enhancing tumor recurrence: a report from the EORTC 26091 TAVAREC Trial

Purpose:Despite recent advances in the molecular characterization of gliomas, it remains unclear which patients benefit most from which second-line treatments. The TAVAREC trial was a randomized, open-label phase II trial assessing the benefit of the addition of the angiogenesis inhibitor bevacizumab to treatment with temozolomide in patients with a first enhancing recurrence of World Health Organization grade 2 or 3 glioma without 1p/19q codeletion. We evaluated the prognostic significance of genome-wide DNA methylation profiles and copy-number variations on the TAVAREC trial samples.Experimental Design:Isocitrate dehydrogenase (IDH) mutation status was determined via Sanger sequencing and IHC. DNA methylation analysis was performed using the MethylationEPIC BeadChip (Illumina) from which 1p/19q codeletion, MGMT promoter methylation (MGMT-STP27), and homozygous deletion of CDKN2A/B were determined. DNA methylation classes were determined according to classifiers developed in Heidelberg and The Cancer Genome Atlas (TCGA; “Heidelberg” and “TCGA” classifier respectively).Results:DNA methylation profiles of 122 samples were successfully determined. As expected, most samples were IDH-mutant (89/122) and MGMT promotor methylated (89/122). Methylation classes were prognostic for time to progression. However, Heidelberg methylation classes determined at time of diagnosis were no longer prognostic following enhancing recurrence of the tumor. In contrast, TCGA methylation classes of primary samples remained prognostic also following enhancing recurrence. Homozygous deletions in CDKN2A/B were found in 10 of 87 IDH-mutated samples and were prognostically unfavorable at recurrence.Conclusions:DNA methylome Heidelberg classification at time of diagnosis is no longer of prognostic value at the time of enhancing recurrence. CDKN2A/B deletion status was predictive of survival from progression of IDH-mutated tumors.Neurolog

The XMM Cluster Survey: Exploring scaling relations and completeness of the Dark Energy Survey Year 3 redMaPPer cluster catalogue

We cross-match and compare characteristics of galaxy clusters identified in observations from two sky surveys using two completely different techniques. One sample is optically selected from the analysis of three years of Dark Energy Survey observations using the redMaPPer cluster detection algorithm. The second is X-ray selected from XMM observations analysed by the XMM Cluster Survey. The samples comprise a total area of 57.4 deg$^2$, bounded by the area of 4 contiguous XMM survey regions that overlap the DES footprint. We find that the X-ray selected sample is fully matched with entries in the redMaPPer catalogue, above $\lambda>$20 and within 0.1$< z <$0.9. Conversely, only 38\% of the redMaPPer catalogue is matched to an X-ray extended source. Next, using 120 optically clusters and 184 X-ray selected clusters, we investigate the form of the X-ray luminosity-temperature ($L_{X}-T_{X}$), luminosity-richness ($L_{X}-\lambda$) and temperature-richness ($T_{X}-\lambda$) scaling relations. We find that the fitted forms of the $L_{X}-T_{X}$ relations are consistent between the two selection methods and also with other studies in the literature. However, we find tentative evidence for a steepening of the slope of the relation for low richness systems in the X-ray selected sample. When considering the scaling of richness with X-ray properties, we again find consistency in the relations (i.e., $L_{X}-\lambda$ and $T_{X}-\lambda$) between the optical and X-ray selected samples. This is contrary to previous similar works that find a significant increase in the scatter of the luminosity scaling relation for X-ray selected samples compared to optically selected samples.Comment: Accepted for publication to MNRA

Persistency of lactation using random regression models and different fixed regression modeling approaches

Milk yield test-day records on the first three lactations of 25,500 Holstein cows were used to estimate genetic parameters and predict breeding values for nine measures of persistency and 305-d milk yield in a random regression animal model using two criteria to define the fixed regression. Legendre polynomials of fourth and fifth orders were used to model the fixed and random regressions of lactation curves. The fixed regressions were adjusted for average milk yield on populations (single) or subpopulations (multiple) formed by cows that calved at the same age and in the same season. Akaike Information (AIC) and Bayesian Information (BIC) criteria indicated that models with multiple regression lactation curves had the best fit to test-day milk records of first lactations, while models with a single regression curve had the best fit for the second and third lactations. Heritability and genetic correlation estimates between persistency and milk yield differed significantly depending on the lactation order and the measures of persistency used. These parameters did not differ significantly depending on the criteria used for defining the fixed regressions for lactation curves. In general, the heritability estimates were higher for first (0.07 to 0.43), followed by the second (0.08 to 0.21) and third (0.04 to 0.10) lactation. The rank of sires resulting from the processes of genetic evaluation for milk yield or persistency using random regression models differed according to the criteria used for determining the fixed regression of lactation curve